{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalComment":"Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \\> 2 years), and disease histology (FL, MZL).","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.7","upperLimit":"83.4","value":"77.5"},{"groupId":"OG001","lowerLimit":"45.8","upperLimit":"60.8","value":"53.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Percentage of participants with an objective response is defined as having a response of at least a PR during the study without administration of new anti-lymphoma therapy. A complete response = a complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities; a partial response (PR) = 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab 375 mg/m\\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \\< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.","id":"OG000","title":"Rituximab + Lenalidomide (R^2)"},{"description":"Participants received rituximab 375 mg/m\\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up to 12 cycles.","id":"OG001","title":"Rituximab + Placebo"}],"paramType":"NUMBER","populationDescription":"The ITT population was defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.","reportingStatus":"POSTED","timeFrame":"From date of first dose to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm","title":"Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}